KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

PReCedeNT trial: Phase III randomized-controlled trial of Lutetium - 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Ameya D Puranik, Indraja D Dev, Sushil Yadav, Venkatesh Rangarajan, Archi Agrawal, Sandip Basu, Vikram A Chaudhari, Anant Ramaswamy, Vikas Ostwal, Manish S Bhandare, Shailesh V Shrikhande, Rahul V Parghane, Prabhat Bhargava, Munita M Bal, Subhash Yadav, Shraddha Patkar, Mahesh Goel, Nilendu C Purandare, Sneha Shah, Sayak Choudhury, Suchismita Ghosh, Manikandan Venkatachalam

BMC Cancer 25(1) 1659

PMID41152774
PMCIDPMC12560366
DOI10.1186/s12885-025-15111-x
发表日期2025-10-29
摘要

摘要

BACKGROUND: Peptide receptor radionuclide therapy (PRRT) with Lutetium-177 DOTATATE is the standard of care for well-differentiated metastatic or locally advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, tumor heterogeneity, particularly in FDG-avid tumors, can limit treatment effectiveness. The PReCedeNT trial aims to evaluate the efficacy of combining PRRT with capecitabine and temozolomide (CAPE-TEM) chemotherapy compared to PRRT alone in patients with FDG-avid, well-differentiated GEP-NETs. METHODS: This single-center, randomized, open-label, phase III trial will enroll patients with FDG-avid, well-differentiated GEP-NETs. Participants will be randomized in a 1:1 ratio to receive either PRRT alone or PRRT plus CAPE-TEM chemotherapy. The primary endpoint is progression-free survival (PFS), with secondary endpoints including objective response rate, overall survival, toxicity, and quality of life parameters. The sample size of 162 patients was calculated based on the assumption that the addition of chemotherapy would improve PFS by an absolute value of 15% compared to the PRRT arm of the NETTER-1 trial. DISCUSSION: The combination of PRRT and chemotherapy may enhance treatment efficacy by targeting both somatostatin receptor-positive and FDG-avid tumor cells. By addressing the lack of prospective data on the efficacy of PRRT combined with chemotherapy in NETs, this trial aims to provide valuable insights into the benefits and risks of this combination. The results of this study have the potential to significantly impact the treatment strategies for patients with aggressive NETs, potentially improving the outcomes and quality of life of this patient population. TRIAL REGISTRATION: This trial is registered with the Clinical Trials Registry of India (CTRI/2019/07/027255) and ClinicalTrials.gov ID: NCT07185672.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。